These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35791043)

  • 1. Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis.
    Shanthikumar S; Ranganathan S; Neeland MR
    Pediatr Pulmonol; 2022 Oct; 57(10):2549-2552. PubMed ID: 35791043
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
    Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
    Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor.
    Mainz JG; Michl RK; Beiersdorf N; Lorenz M; Schneider U; Groten T; Jaudszus A
    Klin Padiatr; 2019 Sep; 231(5):271-273. PubMed ID: 31408905
    [No Abstract]   [Full Text] [Related]  

  • 5. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
    Talamo Guevara M; McColley SA
    Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.
    Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N
    Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
    Schneider EK; Reyes-Ortega F; Li J; Velkov T
    Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
    McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS
    Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
    Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
    Elborn JS; Ramsey B; Wainwright C; Boyle M
    Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855
    [No Abstract]   [Full Text] [Related]  

  • 12. Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis.
    Tétard C; Mittaine M; Bui S; Beaufils F; Maumus P; Fayon M; Burgel PR; Lamireau T; Delhaes L; Mas E; Enaud R
    J Pediatr Gastroenterol Nutr; 2020 Dec; 71(6):778-781. PubMed ID: 32740537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
    Bitonti M; Fritts L; So TY
    J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
    Casciaro R; Costa S; Dang P; Majo F; Ros M
    Clin Respir J; 2018 Apr; 12(4):1767-1768. PubMed ID: 28759146
    [No Abstract]   [Full Text] [Related]  

  • 17. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.
    Moheet A; Beisang D; Zhang L; Sagel SD; VanDalfsen JM; Heltshe SL; Frederick C; Mann M; Antos N; Billings J; Rowe SM; Moran A;
    J Cyst Fibros; 2021 Mar; 20(2):333-338. PubMed ID: 32917547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis.
    Deeks ED
    Drugs; 2016 Aug; 76(12):1191-201. PubMed ID: 27394157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis.
    Gelzo M; Iacotucci P; Caputo M; Cernera G; Comegna M; Carnovale V; Corso G; Castaldo G
    J Cyst Fibros; 2021 Jan; 20(1):e1-e6. PubMed ID: 32586737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor.
    Singh SB; McLearn-Montz AJ; Milavetz F; Gates LK; Fox C; Murry LT; Sabus A; Porterfield HS; Fischer AJ
    Pediatr Pulmonol; 2019 Aug; 54(8):1200-1208. PubMed ID: 31012285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.